[APPLICATION CLOSED] Bacteria living on surfaces are called biofilms, and they cause up to 80% of all infections. Biofilms are difficult to eradicate using systemic antibiotic treatments and can necessitate…
Read more[APPLICATION CLOSED] Position: Laboratory Assistant/Laboratory Technician at Promimic Company: Promimic is a world leader in new disruptive technologies for nano surface modification of implants that greatly improves osseointegration and restoring…
Read more[APPLICATION CLOSED] Promimic is a world leader in new disruptive technologies for nano surface modification of implants, greatly improving osseointegration. Our 20 nanometer thin surface treatment, HAnano Surface, is commercially…
Read more[APPLICATION CLOSED] Titanium and cobalt-chrome are frequently used as implant materials in dentistry and orthopedics. Ion release from the implant to the surrounding tissue after implantation always occur, and normally…
Read more[APPLICATION CLOSED] Bacteria living on surfaces are called biofilms and they cause up to 80% of all infections. They are difficult to eradicate using antibiotics and can be the reason…
Read morePromimic and Curiteva have been working together to incorporate the Promimic surface technology with Curiteva’s new 3D-printed porous PEEK cervical implant for spinal fusion. “We have a great partnership, and…
Read moreAim is to grow processing of HAnano surface treated medical implants Press release I Warsaw, Indiana, USA and Molndal, Sweden | July 28, 2022 Promimic AB and Danco Medical –…
Read moreIf you’re looking for a way to elevate your implant above the competition, visit Promimic (Booth 246) at OMTEC this week to learn about our HAnano Surface. The nano-thin surface…
Read moreAktieägarna i Promimic AB, org.nr 556657-7754, med säte i Mölndal, kallas härmed till extra bolagsstämma tisdagen den 5 april 2022 kl. 13, på AZ BioVenturesHub, HB4, c/o Astra Zeneca R&D…
Read moreAktieägarna i Promimic AB (publ), org.nr 556657-7754, med säte i Mölndal, kallas härmed till årsstämma måndagen den 14 mars 2022 kl. 13.00, på AZ BioVenturesHub, HB4, c/o Astra Zeneca R&D…
Read more